George Mondinde Ikomey1, Marie Claire Okomo Assoumou2, Josiah Otwoma Gichana3, Duncan Njenda4, Sello Given Mikasi4, Martha Mesembe5, Emilia Lyonga6, Graeme Brendon Jacobs7. 1. PhD, Center for the Study and Control of Communicable Diseases (CSCCD), Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, PO Box 8445, Yaoundé, Cameroon. 2. PhD, Center for the Study and Control of Communicable Diseases (CSCCD) Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, PO Box 8445, Yaoundé, Cameroon. 3. BSc, Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Tygerberg 7505, South Africa. 4. MSc, Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Tygerberg 7505, South Africa. 5. BSc, Center for the Study and Control of Communicable Diseases (CSCCD) Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, PO Box 8445, Yaoundé, Cameroon. 6. MSc, Center for the Study and Control of Communicable Diseases (CSCCD) Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, PO Box 8445, Yaoundé, Cameroon. 7. PhD, Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Tygerberg 7505, South Africa.
Abstract
INTRODUCTION: The emergence of drug resistance mutations (DRMs) has been a major threat for successful lifelong combination antiretroviral therapy (cART), especially for HIV-vertically infected children within the context of the prevention of mother-to-child transmission (PMTCT). This study aimed to evaluate DRMs amongst immune competent treatment-naïve children in Cameroon. METHODS: A cross-sectional study was conducted between 2015 and 2016 amongst 55 proxy consented HIV-1 positive children, aged 9 months to 6 years. They were all immune competent, cART naïve and with unknown history of PMTCT. CD4 cell counts and genotypic drug resistance testing were performed using standard methods. RESULTS: Levels of DRMs to protease (PR) inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs were 27.6%, 3.7% and 40.7%, respectively. Only minor DRMs were observed for PR. The observed mutations for NRTI were K65R, T215I and K219E (33.0% each) and for NNRTI: V106M, Y181C and Y188H (6.0% each). Only minor accessory mutations were found in the integrase (IN) region. CONCLUSION: Despite widely available cART we still observe naïve HIV children, especially from the rural communities. We observe that a proportion of study participants had HIV-1 drug resistance associated mutations (RAMs). Data generated could help strengthen the current PMTCT programmes within the country. There is a need to upscale approaches for drug resistance testing for children in Cameroon and many other resource-limited settings.
INTRODUCTION: The emergence of drug resistance mutations (DRMs) has been a major threat for successful lifelong combination antiretroviral therapy (cART), especially for HIV-vertically infected children within the context of the prevention of mother-to-child transmission (PMTCT). This study aimed to evaluate DRMs amongst immune competent treatment-naïve children in Cameroon. METHODS: A cross-sectional study was conducted between 2015 and 2016 amongst 55 proxy consented HIV-1 positive children, aged 9 months to 6 years. They were all immune competent, cART naïve and with unknown history of PMTCT. CD4 cell counts and genotypic drug resistance testing were performed using standard methods. RESULTS: Levels of DRMs to protease (PR) inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs were 27.6%, 3.7% and 40.7%, respectively. Only minor DRMs were observed for PR. The observed mutations for NRTI were K65R, T215I and K219E (33.0% each) and for NNRTI: V106M, Y181C and Y188H (6.0% each). Only minor accessory mutations were found in the integrase (IN) region. CONCLUSION: Despite widely available cART we still observe naïve HIV children, especially from the rural communities. We observe that a proportion of study participants had HIV-1 drug resistance associated mutations (RAMs). Data generated could help strengthen the current PMTCT programmes within the country. There is a need to upscale approaches for drug resistance testing for children in Cameroon and many other resource-limited settings.
Authors: Jean-Christophe Plantier; Raoudha Dachraoui; Véronique Lemée; Marie Gueudin; Françoise Borsa-Lebas; François Caron; François Simon Journal: AIDS Date: 2005-03-04 Impact factor: 4.177
Authors: Serge C Billong; Joseph Fokam; Avelin F Aghokeng; Pascal Milenge; Etienne Kembou; Ibile Abessouguie; Flore Beatrice Meva'a-Onglene; Anne C Zoung-Kanyi Bissek; Vittorio Colizzi; Eitel N Mpoudi; Jean-Bosco N Elat; Koulla S Shiro Journal: PLoS One Date: 2013-08-26 Impact factor: 3.240
Authors: Avelin F Aghokeng; Charles Kouanfack; Sabrina Eymard-Duvernay; Christelle Butel; Ginette E Edoul; Christian Laurent; Sinata Koulla-Shiro; Eric Delaporte; Eitel Mpoudi-Ngole; Martine Peeters Journal: J Int AIDS Soc Date: 2013-01-31 Impact factor: 5.396
Authors: Joseph Fokam; Serge C Billong; Anne C Z K Bissek; Etienne Kembou; Pascal Milenge; Ibile Abessouguie; Armand S Nkwescheu; Zephirin Tsomo; Avelin F Aghokeng; Grace D Ngute; Peter M Ndumbe; Vittorio Colizzi; Jean B N Elat Journal: BMC Public Health Date: 2013-04-08 Impact factor: 3.295